![ADDING MULTIMEDIA Teva Announces U.S. Approval of AJOVYTM (fremanezumab-vfrm) Injection, the First and Only Anti-CGRP Treatment with Both Quarterly and Monthly Dosing for the Preventive Treatment of Migraine in Adults | Business ADDING MULTIMEDIA Teva Announces U.S. Approval of AJOVYTM (fremanezumab-vfrm) Injection, the First and Only Anti-CGRP Treatment with Both Quarterly and Monthly Dosing for the Preventive Treatment of Migraine in Adults | Business](https://mms.businesswire.com/media/20180914005613/en/678526/5/AJOVY+Image.jpg?download=1)
ADDING MULTIMEDIA Teva Announces U.S. Approval of AJOVYTM (fremanezumab-vfrm) Injection, the First and Only Anti-CGRP Treatment with Both Quarterly and Monthly Dosing for the Preventive Treatment of Migraine in Adults | Business
![Teva Reports First Quarter 2023 Financial Results and Reaffirms 2023 Non-GAAP Outlook | Business Wire Teva Reports First Quarter 2023 Financial Results and Reaffirms 2023 Non-GAAP Outlook | Business Wire](https://mms.businesswire.com/media/20230510005122/en/1789379/4/Infographic_Q1_2023.jpg)
Teva Reports First Quarter 2023 Financial Results and Reaffirms 2023 Non-GAAP Outlook | Business Wire
![The Procter & Gamble Company and Teva Pharmaceutical Industries Announce Formation of New Consumer Health Care Partnership | Procter & Gamble News The Procter & Gamble Company and Teva Pharmaceutical Industries Announce Formation of New Consumer Health Care Partnership | Procter & Gamble News](https://s25.q4cdn.com/264117071/files/doc_multimedia/2011/11/World's-Leading-Seller-of-Medicines@lowres.png)